TrialMaster® EDC selected by leading Israeli data management and biostatistics firm
Fort Lauderdale, FL, April 11, 2016 - OmniComm Systems, Inc., a global leading provider of clinical data management technology, today announced the signing an agreement with Medistat Ltd., a leading data management and biostatistics organization, headquartered in Tel Aviv, Israel. OmniComm’s TrialMaster electronic data capture (EDC) suite will be used to address the clinical trial needs of the growing Israeli life sciences sector which consists of more than 1300 organizations. “We are pleased that OmniComm Systems is realizing the value of the Israeli market and the position of Medistat as a global provider of data management and biostatistician solutions,” said Dr. Gil Harari President and CEO of Medistat, “We truly believe that the cooperation with OmniComm will be a key factor to becoming a leader in the rapidly growing Intelligent EDC market in Israel and worldwide.”
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.
FDA Grants Ziftomenib with Breakthrough Therapy Designation for NPM1-Mutant Acute Myeloid Leukemia
April 23rd 2024Data from the Phase Ib portion of the KOMET-001 trial showed that the once-daily oral treatment may provide a substantial improvement over available therapies for relapsed/refractory NPM1-mutant acute myeloid leukemia.